If you have been reading about GW501516 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-11. Numbers and descriptions here follow the published literature rather than marketing material.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
=== Allegations of patent infringement on mRNA technology (2022) === In August 2022, Moderna announced that it will sue Pfizer and its partner BioNTech for infringing its patent on the mRNA technology. In May 2024, the European Patent Office upheld the validity of Moderna's EP949 patent, one of the two patents asserted against Pfizer and BioNTech.
One Mesopotamian myth, a historiographic poem entitled "The curse of Akkad: the Ekur avenged", explains how the empire created by Sargon of Akkad fell and the city of Akkad was destroyed. The myth was written hundreds of years after Naram-Sin's life and is the poet's attempt to explain how the Gutians succeeded in conquering Sumer. After an opening passage describing the glory of Akkad before its destruction, the poem tells of how Naram-Sin angered the chief god Enlil by plundering the Ekur (Enlil's temple in Nippur.) In his rage, Enlil summoned the Gutians down from the hills east of the Tigris, bringing plague, famine and death throughout Mesopotamia. Food prices became vastly inflated, with the poem stating that 1 lamb would buy only half a sila (about 425 ml or 14.4 US fl oz) of grain, half a sila of oil, or half a mina (about 250 g or 8.8 oz) of wool. To prevent this destruction, eight of the gods (namely Inanna, Enki, Sin, Ninurta, Utu, Ishkur, Nusku, and Nidaba) decreed that the city of Akkad should be destroyed in order to spare the rest of Sumer and cursed it.
=== Regional === The West Yorkshire Combined Authority is a strategic authority established in 2014. It allows the five metropolitan borough councils to collaborate. The authority was restructured in 2021 to be led by a directly elected mayor, the Mayor of West Yorkshire, and at the same time gained additional powers over areas including education, housing, and planning. The current mayor is Tracy Brabin, who was first elected in 2021 and successfully defended her seat in 2024. As part of the establishment of the combined authority, the West Yorkshire Passenger Transport Executive was abolished and its functions transferred to the new authority.
Sources: en.wikipedia.org
The first island chain is the first string of major Pacific archipelagos out from the East Asian continental mainland coast. It is principally composed of the Kuril Islands, the Japanese archipelago, the Ryukyu Islands, Taiwan (Formosa), the northern Philippines, and Borneo, extending all the way from the Kamchatka Peninsula in the northeast to the Malay Peninsula in the southwest. The first island chain is one of three island chain doctrines within the island chain strategy of US foreign policy. It is considered a strategic military barrier to accessing the wider Pacific Ocean given the relative shallowness of waters to the west of the first island chain, which has important implications for submarine detection.
== Homicides == Thailand ranked 30 of 216 countries for its number of homicides (2,387) in 2015. Other ASEAN nations ranked: Philippines, 14 (9,756 homicides); Vietnam, 39 (1,358); Myanmar, 41 (1,304); Indonesia, 42 (1,277); Malaysia, 74 (540); Laos, 79 (467); Cambodia, 100 (268); Singapore, 175 (14); Brunei, 197 (2). Among ASEAN nations, the Philippines had the highest rate of homicides per 100,000 population (9.84), followed by Laos (6.87), and Thailand (3.51). Singapore had the lowest homicide rate in ASEAN, with just 0.25 murders per 100,000 population.
I. Bilobed flap The design of the bilobed flap derives from the creation of two adjacent random transposition flaps (lobes). In its original design, the leading flap is applied to cover the defect, and the second flap, is emplaced where the skin flexes more, and fills the donor-site wound (from where the first flap was harvested), which then is closed primarily, with sutures. The first flap is oriented geometrically, at 90 degrees from the long axis of the wound (defect), and the second flap is oriented 180 degrees from the axis of the wound. Although effective, the bilobed flap technique did create troublesome "dog ears" of excess flesh that required trimming and it also produced a broad skin-donor area that was difficult to confine to the nose. In 1989, J. A. Zitelli modified the bilobed flap technique by: (a) orienting the leading flap at 45 degrees from the long axis of the wound; and (b) orienting the second flap at 90 degrees from the axis of the wound. Said orientations and emplacements eliminated the excess-flesh "dog ears", and thus required a smaller area of donor skin; resultantly, the broad-based, bilobed flap is less prone to the "trap door" and the "pin cushion" deformities common to skin-flap transposition procedure.
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.